Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin

Diabetes

Volumn 63, Issue 8, 2014, Pages 2776-2787

  Wu, Tongzhi ^a   Ma, Jing ^a   Bound, Michelle J ^a   Checklin, Helen ^a   Deacon, Carolyn F ^b   Jones, Karen L ^a   Horowitz, Michael ^a   Rayner, Christopher K ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENERGY INTAKE; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL MOTILITY; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; METFORMIN; OBESITY; PYRAZINES; TRIAZOLES;

EID: 84905019254     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1627     Document Type: Article

References (53)

1. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007; 30: 1335-1343
2. Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003; 52:380-386
3. Nauck MA, Heimesaat MM, Orskov C, Holst J.J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91:301-307
4. Schirra J, Göke B. The physiological role of GLP-1 in human: incretin, ileal brake or more? Regul Pept 2005; 128:109-115
5. Gutzwiller JP, Göke B, Drewe J., et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999; 44:81-86
6. Schirra J, Nicolaus M, Roggel R., et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006; 55:243-251
7. Deane AM, Nguyen NQ, Stevens J.E., et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010; 95:215-221
8. Pilichiewicz AN, Chaikomin R, Brennan I.M., et al. Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men. Am J Physiol Endocrinol Metab 2007; 293:E743-E753
9. Ma J, Pilichiewicz AN, Feinle-Bisset C, et al. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes. Diabet Med 2012; 29:604-608
10. Seimon RV, Brennan IM, Russo A, et al Gastric emptying, mouth-to-cecum transit, and glycemic, insulin, incretin, and energy intake responses to a mixed-nutrient liquid in lean, overweight, and obese males. Am J Physiol Endocrinol Metab 2013; 304:E294-E300
11. Muscelli E, Mari A, Casolaro A., et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008; 57:1340-1348
12. Vollmer K, Holst JJ, Baller B, et al Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008; 57:678-687
13. Theodorakis MJ, Carlson O, Michopoulos S., et al. Human duodenal entero-endocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 2006; 290:E550-E559
14. Brener W, Hendrix TR, McHugh PR Regulation of the gastric emptying of glucose. Gastroenterology 1983; 85:76-82
15. Horowitz M, O'Donovan D, Jones KL, Feinle C, Rayner C.K., Samsom M. Gastric emptying in diabetes: clinical significance and treatment. Diabet Med 2002; 19:177-194
16. Woerle HJ, Lindenberger T, Linke R., et al. A single dose of vildagliptin decelerates gastric emptying in patients with type 2 diabetes. Paper presented at the 67th Scientific Sessions of the American Diabetes Association; June 2007; Chicago, IL
17. Vella A, Bock G, Giesler P.D., et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007; 56:1475-1480
18. Wu T, Bound MJ, Zhao B.R., et al. Effects of a D-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes. Diabetes Care 2013; 36:1913-1918
19. Stevens JE, Horowitz M, Deacon C.F., Nauck M., Rayner CK, Jones KL. The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study. Aliment Pharmacol Ther 2012; 36:379-390
20. Aulinger BA, Bedorf A, Kutscherauer G., et al. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade. Diabetes 2013; 63:1079-1092
21. Nonaka T, Sekino Y, Iida H., et al. Early effect of single-dose sitagliptin administration on gastric emptying: crossover study using the (13)C breath test. J Neurogastroenterol Motil 2013; 19:227-232
22. Vella A, Bock G, Giesler P.D., et al. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. Clin Endocrinol (Oxf) 2008; 69:737-744
23. Ahrén B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab 2007; 21: 517-533
24. Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab 2014; 16: 30-37
25. Maida A, Lamont BJ, Cao X, Drucker DJ Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia 2011; 54:339-349
26. Migoya EM, Bergeron R, Miller J.L., et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010; 88:801-808
27. Lenhard JM, Croom DK, Minnick DT Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Commun 2004; 324:92-97
28. Hinke SA, Kühn-Wache K, Hoffmann T, Pederson RA, McIntosh CH, Demuth HU. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002; 291:1302-1308
29. Solis-Herrera C., Triplitt C, Garduno-Garcia J de J, Adams J, DeFronzo R.A., Cersosimo E. Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study. Diabetes Care 2013; 36:2756-2762
30. Feltrin KL, Little TJ, Meyer J.H., et al. Effects of intraduodenal fatty acids on appetite, antropyloroduodenal motility, and plasma CCK and GLP-1 in humans vary with their chain length. Am J Physiol Regul Integr Comp Physiol 2004; 287: R524-R533
31. Vilsbøll T., Krarup T, Sonne J., et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003; 88:2706-2713
32. Lindgren O, Carr RD, Deacon C.F., et al. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin En-docrinol Metab 2011; 96:2519-2524
33. Herzberg-Schäfer SA, Staiger H, Heni M, et al. Evaluation of fasting state-/ oral glucose tolerance test-derived measures of insulin release for the detection of genetically impaired β-cell function. PLoS One 2010; 5:e14194
34. Lugari R, Dei Cas A, Ugolotti D, et al Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res 2004; 36:111-115
35. Ryskjaer J, Deacon CF, Carr R.D., et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 2006; 155:485-493
36. Anini Y, Brubaker PL Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 2003; 52:252-259
37. Deacon CF, Wamberg S, Bie P., Hughes TE, Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 2002; 172:355-362
38. Herman GA, Bergman A, Stevens C., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91:4612-4619
39. El-Ouaghlidi A., Rehring E, Holst J.J., et al. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory poly-peptide secretion. J Clin Endocrinol Metab 2007; 92:4165-4171
40. Irwin N, Flatt PR Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia 2009; 52:1724-1731
41. Højberg PV, Vilsbøll T, Rabøl R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009; 52:199-207
42. Christensen M, Calanna S, Holst J.J., Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. J Clin Endocrinol Metab 10 December 2013 [Epub ahead of print]
43. Mulherin AJ, Oh AH, Kim H, Grieco A., Lauffer LM, Brubaker PL. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 2011; 152:4610-4619
44. Cho YM, Kieffer TJ New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia 2011; 54:219-222
45. Eshghi SR, Bell GJ, Boulé NG. Effects of aerobic exercise with or without metformin on plasma incretins in type 2 diabetes. Can J Diabetes 2013; 37:375-380
46. Bailey CJ, Turner RC Metformin. N Engl J Med 1996; 334:574-579
47. Miller RA, Chu Q, Xie J., Foretz M, Viollet B, Birnbaum MJ Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013; 494:256-260
48. Gu W, Yan H, Winters K.A., et al. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. J Pharmacol Exp Ther 2009; 331:871-881
49. Ferner RE, Rawlins MD, Alberti KG Impaired beta-cell responses improve when fasting blood glucose concentration is reduced in non-insulin-dependent diabetes. Q J Med 1988; 66:137-146
50. Witte AB, Grybäck P, Holst J.J., et al. Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man. Regul Pept 2009; 158:57-62
51. Batterham RL, Cowley MA, Small C.J., et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418:650-654
52. Lee A, Morley JE Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 1998; 6:47-53
53. Trahair LG, Horowitz M, Rayner C.K., et al. Comparative effects of variations in duodenal glucose load on glycemic, insulinemic, and incretin responses in healthy young and older subjects. J Clin Endocrinol Metab 2012; 97:844-851